Related Experiment Video
Updated: Apr 30, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Rare variants and cardiovascular disease
Insights
Genetic studies reveal common variants explain little cardiovascular disease (CVD) risk. Rare variants in monogenic CVDs and genome-wide association studies (GWASs) are converging to uncover key biological mechanisms.
Area of Science:
- Genetics
- Cardiology
- Genomics
Background:
- Cardiovascular disease (CVD) is a major cause of death and illness globally.
- Genome-wide association studies (GWASs) have identified common genetic variants associated with CVD and its risk factors, but explain little phenotypic variance.
- Studies of monogenic cardiovascular diseases (CVDs) have identified genes crucial to disease etiology.
Purpose of the Study:
- To review how findings from rare variant studies in monogenic CVDs and GWASs of common variants are converging.
- To provide further insight into the biological mechanisms underlying cardiovascular disease.
Main Methods:
- Review of existing literature on genetic studies of cardiovascular disease.
- Analysis of findings from genome-wide association studies (GWASs) of common variants.
- Examination of studies on rare variants in monogenic cardiovascular diseases.
Main Results:
- Common variants identified through GWASs explain a small proportion of CVD phenotypic variance.
- Rare variants are hypothesized to contribute to the missing heritability in CVD.
- Studies of monogenic CVDs have successfully identified key genes involved in disease etiology.
Conclusions:
- Converging evidence from rare variant and common variant studies offers deeper insights into CVD mechanisms.
- Understanding both common and rare genetic variations is crucial for elucidating cardiovascular disease etiology.
- Future research on rare variants in cardiovascular traits is warranted.
Abstract:
Cardiovascular disease (CVD) is a leading cause of mortality and morbidity in the Western world. Large genome-wide association studies (GWASs) of coronary artery disease, myocardial infarction, stroke and dilated cardiomyopathy have identified a number of common genetic variants with modest effects on disease risk. Similarly, studies of important modifiable risk factors of CVD have identified a large number of predominantly common variant associations, for example, with blood pressure and blood lipid levels. In each case, despite the often large numbers of loci identified, only a small proportion of the phenotypic variance is explained. It has been hypothesised that rare variants with large effects may account for some of the missing variance but large-scale studies of rare variation are in their infancy for cardiovascular traits and have yet to produce fruitful results. Studies of monogenic CVDs, inherited disorders believed to be entirely driven by individual rare mutations, have highlighted genes that play a key role in disease aetiology. In this review, we discuss how findings from studies of rare variants in monogenic disease and GWAS of predominantly common variants are converging to provide further insight into biological disease mechanisms.
More Related Videos
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Coronary Artery Disease I: Introduction
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Coronary Artery Disease II: Pathophysiology